News

Evotec extends a biotech deal with $13M on the line

Evotec, a risk-sharing R&D collaborator, has extended its relationship with biotech startup Padlock Therapeutics, inking a new deal that will see the pair progress into preclinical development.

PPD's in-house biotech pairs up with J&J

X-Chem, a subsidiary of PPD, has signed a deal with Johnson & Johnson to provide its library of molecules to aid in the discovery of new treatments for inflammatory disease.

AMRI spends $60M to beef up its manufacturing heft

AMRI, on the mend after a rough quarter, is laying out $60 million to expand its manufacturing footprint, agreeing to buy a couple of outposts from service provider Aptuit.

WuXi buys big into genomics with NextCODE deal

Chinese CRO giant WuXi PharmaTech is continuing its push into genomic sequencing, paying $65 million for NextCODE Health, a Big Data-focused spinout of the high-profile deCODE.

Fujifilm deepens its CMO heft with Kalon buyout

Fujifilm has completed its acquisition of Kalon Biotherapeutics, a contract manufacturer with a focus on vaccines.

Evotec teams up with Ohio State on a new cancer drug

German contract researcher Evotec has paired off with Ohio State to help the school develop an in-house cancer prospect, lending its technology and expertise.

WuXi goes mobile with a chemistry app

China's WuXi PharmaTech has launched an app to allow clients to order its chemistry services on the go, touting it as an industry first as the CRO works to claim more of the small-molecule services market.

GVK feels the sting after data scandal

Improprieties at a GVK Biosciences facility in India have led some European countries to pull medicines from shelves, and the resulting fallout is cutting into the CRO's profits.

Covance could face fines over animal deaths

A malfunctioning thermostat led to the deaths of 13 research primates at a Covance facility, according to authorities, and the CRO could be in line for federal punishment.

PPD bets on Japan with new joint venture

PPD has signed a deal with service provider Shin Nippon Biomedical Laboratories to collaborate in Japan, pooling resources in a joint venture designed to tap the growing market for clinical research there.

PPD's X-Chem strikes another deal with Bayer

X-Chem, the biotech that operates from within PPD, signed a second agreement with partner Bayer, outlicensing a second discovery-stage program.

Evotec banks $10M from its risk-sharing research projects

German contract developer Evotec pocketed €8 million ($10 million) from its ongoing R&D collaborations with Bayer and Johnson & Johnson, capping a big year for the innovative company.

Poland's KCR expands its Euro reach with latest deal

Contract researcher KCR is dialing up its presence in Ukraine, buying out a competitor's whole clinical portfolio and doubling down on a country it believes is ripe for R&D growth.

WuXi reaches into the biopharma hubs of Boston and San Francisco

WuXi PharmaTech, China's largest CRO, is blueprinting forays into two of the hottest locales for U.S. R&D, planning to open offices in Boston and San Francisco.

PPD partners up with ERT for data collection

PPD has signed a data-minded deal with the collection experts at ERT, a partnership the companies believe will help their clients conduct more efficient trials.

After CEO's death, Health Decisions brings in a Quintiles vet to lead its transition

Health Decisions, a week removed from the plane crash that claimed the life of its CEO, has recruited a CRO veteran from the University of North Carolina to step in as interim chief executive and oversee its transition.

BioClinica snags a Pfizer exec to take the helm

BioClinica, fresh from its latest merger, has named a Pfizer executive as its next CEO.

CRO Health Decisions carries on after CEO's death

North Carolina CRO Health Decisions is working its way back to normalcy after the death of its founder and CEO, processing a loss that "devastated" its staff, an executive said.

Investor cries foul over Covance's $6B sale to LabCorp

Covance got some bad advice when it agreed to a roughly $6 billion buyout from LabCorp, according to an investor lawsuit, which alleges that chief dealbroker Goldman Sachs had a conflict of interest all along.

DaVita grows its in-house CRO with a data-centric merger

Kidney dialysis magnate DaVita HealthCare Partners has merged its two research-minded subsidiaries to create an end-to-end CRO focused on renal trials.